B. Mayinger et J. Hensen, Nonpeptide vasopressin antagonists: A new group of hormone blockers entering the scene, EXP CL E D, 107(3), 1999, pp. 157-165
Citations number
90
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
After the story of success of hormone blockers for catecholamines, aldoster
one and angiotensin II and their successful implementation into clinical pr
actice another endocrine cardiovascular system has come into focus. It has
long been known, that the hormone vasopressin plays an important role in pe
ripheral vasoconstriction, hypertension and in several disease conditions w
ith dilutional hyponatremia in edematous disorders, like congestive heart f
ailure, liver cirrhosis, SIADH and nephrotic syndrome. A series of orally a
ctive nonpeptide antagonists against the vasopressin receptor subtypes has
recently been synthesized and is now under intensive examination. Nonpeptid
e V-1a-receptor specific antagonists, OPC 21268 and SR 49059, nonpeptide V-
2-receptor specific antagonists, SR 121463 A and VPA 985, and combined V-1a
-/V-2-receptor antagonists, OPC 31260 and YM 087, have become available for
clinical research. AVP-V-2-receptor antagonists lead to a dose-dependent d
iabetes insipidus in animals and man. The term aquaretic drugs (aquaretics)
has been coined for these drugs to highlight their different mechanism com
pared to the saluretic diuretic furosemide. V-1a-receptor antagonists might
offer new therapeutic advantages in the treatment of vasoconstriction and
hypertension. Combined V-1a-/V-2-receptor antagonists might be beneficial i
n the treatment of congestive heart failure. Early results are promising an
d now need to be confirmed in large clinical studies.